Ethnic disparity in HIV prevalence and zidovudine treatment among childbearing women and pediatric AIDS cases in California

AIDS

Volumn 16, Issue 18, 2002, Pages 2469-2472

  Ruiz, Juan D ^a   Molitor, Fred ^b   Bruckner, Tim ^c   Zukowski, Donna ^a  

^a CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^b ETR ASSOCIATES   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Childbearing women; Pediatric AIDS; Racial ethnic disparities; Zidovudine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; LAMIVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; COUNSELING; ETHNOLOGY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; SCREENING; THIRD TRIMESTER PREGNANCY; UNITED STATES;

ADULT; AFRICAN AMERICANS; ANTI-HIV AGENTS; CALIFORNIA; CROSS-SECTIONAL STUDIES; FEMALE; HISPANIC AMERICANS; HIV INFECTIONS; HUMANS; INFANT; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVALENCE; ZIDOVUDINE;

EID: 0037032907     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200212060-00013     Document Type: Article

References (25)

1. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, vol. 11. Atlanta, GA, USA; 1999, pp. 1-24.
2. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MI, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994, 331:1173-1180.
3. Centers for Disease Control and Prevention. Recommendations of the Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR 1994, 43(RR-11):282-288.
4. Centers for Disease Control and Prevention. Public Health Service Recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women. MMWR 1995, 44(RR.7):1-15.
5. Bulterys M. Preventing vertical HIV transmission in the year 2000: Progress and prospects - A review. Placenta 2001, 22 (Suppl. A):S5-S12.
6. Lindegren ML, Steinberg S, Byers RH Epidemiolugy of HIV/AIDS in children. Pediatr Clin North Am 2000, 47:1-20.
7. Lindegren ML, Byers RH Jr, Thomas P, Davis SF, Caldwell B, Rogers M, et al. Trends in perinatal transmission of HIV/AIDS in the United States. JAMA 1999, 282:S31-538.
8. Mofenson LM, Fowler MG. Interruption of materno-fetal transmission. AIDS 1999, 13 (Suppl A):S205-5214.
9. Shaffer N, Chuachoowong R, Mock PA, Bhadrakom C, Siriwasin W, Young NL, et al. Shorl-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: A randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet 1999, 353:773-780.
10. Leroy V, Karon JM, Alioum A, Ekpini ER, Meda N, Greenberg AE, et al. Twenty-four month efficacy of a maternal short-course zidovudine regimen to prevent mother-to-child transmission of HIV-1 in West Africa. AIDS 2002, 16:631-641.
11. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): A randomised, double-blind, placebo-controlled trial. Lancet 2002, 359:1178-1186.
12. Wortley PM, Fleming PF. AIDS in women in the United States. JAMA 1997, 278:911-916.
13. Gwinn M, Pappaioanou M, George JR, Hannon WH, Wasser SC, Redus MA, et al. Prevalence of HIV infection in childbearing women in the United States. JAMA 1991, 265:1704-1708.
14. Mei JV, Hannon WH, Dobhs TL, Bell CI, Spruill C, Gwinn M. Radioimmunoassay for monitoring zidovudine in dried blood spot specimens. Clin Chem 1998, 44:281-286.
15. US Department of Health and Human Services. Neonatal HIV-1 Laboratory Procedures (brochure). Serologic Assays for Human Immunodeficiency Virus Antibody in Dried-Blood Specimens Collected on Filter Paper from Neonates [Protocoll; 1989.
16. Tadepalli SM, Puckett L, Jeal S, Kanics L, Quinn RP. Differential assay of zidovudine and its glucuronide metabolite in serum and urine with a radioimmunoassay kit. Clin Chem 1990, 36: 897-900.
17. Quinn RP, Orban B, Tadepalli S. Radioimmunoassay for retrovir, an anti-human immunodeficiency virus drug. J Immunoassay 1989, 10:177-189.
18. Census 2000, Summary File 1 General File 1. State of California: Department of Finance, Demographic Research Unit. Available at http://www.dof.ca.gov/HTML/DEMOGRAP/SF1CA.pdf. Accessed 17 July 2002.
19. Frisbie WP, Echevarria S, Hummer RA. Prenatal care utilization among non-Hispanic whites, African Americans, and Mexican Americans. Matern Child Health J 2001, 5:21-33.
20. Beck LF, Morrow B, Lipscomb LE, Johnson CH, Gaffield ME, Rogers M, et al. Prevalence of selected maternal behaviors and experiences. Pregnancy Risk Assessment Monitoring System (PRAMS), 1999. MMWR 2002, 51 (RR-11):282-288.
21. Tossounian SA, Schoeedorf KC, Kiely JL. Racial differences in perceived barriers to prenatal care. Matern Child Health J 1997, 1:229-236.
22. Sarnoff R, Adams E. Racial and ethnic disparities in the discordance between women's assessment of the timing of their prenatal care entry and the first trimester standard. Matern Child Health J 2001, 5:179-187.
23. Ruiz JD, Molitor F, Prussing E, Peck L, Grasso P. Prenatal HIV counseling and testing in California: Women's experiences and providers' practices. AIDS Educ Prev 2002, 14:190-195.
24. Wade NA, Birkhead GS, Warren BL, Charbonneau TT, French PT, Wang L, et al. Abbreviated regímens of zidowudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998, 339:1409-1414.
25. County of Los Angeles, Department of Health Services. Pattern of HIV-infection in newborns causes concern. Office of Public Health Communications. Available at: http://ladhs.org/media/Accessed 4 February 2002.